Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)* [Yahoo! Finance]
Verona Pharma plc - American Depositary Shares (VRNA)
US:NASDAQ Investor Relations:
nasdaq.com/symbol/vrna/real-time
Company Research
Source: Yahoo! Finance
with a novel mechanism of action in more than 20 years for the maintenance treatment of COPD. COLUMBIA, S.C. Sept. 17, 2024 /PRNewswire/ -- The Ritedose Corporation Inc. (Ritedose), the largest CDMO in the United States specializing in sterile Blow Fill Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets, is proud to partner with Verona Pharma plc (Nasdaq: VRNA) as the development and manufacturing partner of Ohtuvayre, a new novel product for Chronic Obstructive Pulmonary Disease (COPD). The U.S. Food and Drug Administration (FDA) approved Ohtuvayre on June 26 for the maintenance treatment of COPD in adult patients. It is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. Ohtuvayre is delivered through a standard jet nebulizer and is expected to redefine the treatment paradigm for COPD. Despite maintenance therapy in multiple combinations, most COPD patients grapple
Show less
Read more
Impact Snapshot
Event Time:
VRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRNA alerts
High impacting Verona Pharma plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VRNA
News
- Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.MarketBeat
- Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*PR Newswire
- Nontuberculous Mycobacterial Infection Market to Exhibit Growth at a CAGR of 13.4% in the US by 2034 | DelveInsightPR Newswire
- Nontuberculous Mycobacterial Infection Market to Exhibit Growth at a CAGR of 13.4% in the US by 2034 | DelveInsightPR Newswire
- Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.MarketBeat
VRNA
Sec Filings
- 9/13/24 - Form 4
- 9/13/24 - Form 4
- 9/11/24 - Form 144
- VRNA's page on the SEC website